Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 5 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 12134631

    Hydrophilic linkers for antibody drug conjugates

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  2. US 12127536

    Humanized M-CSF mice

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  3. US 12123001

    Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  4. US 12116622

    Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  5. US 12115216

    Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  6. US 12110502

    Models of tauopathy

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  7. US 12103960

    VEGF traps and mini-traps and methods for treating ocular disorders and cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted
  8. US 12096754

    Non-human animals having a humanized lymphocyte-activation gene 3

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  9. US 12090193

    Glucagon-like peptide 1 receptor agonists and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  10. US 12091449

    Anti-PfRH5 antibodies and antigen-binding fragments thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  11. US 12090201

    Methods for treating atopic dermatitis by administering an IL-4R antagonist antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  12. US 12091460

    Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  13. US 12089575

    Genetically modified mouse that expresses humanized PD1 and PD-L1 proteins

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  14. US 12091440

    IL2 and peptide-MHC complex fusion proteins and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  15. US 12084516

    Anti-C5 antibody combinations and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  16. US 12083141

    Treatment of hyperglycemia with solute carrier family 39 member 5 (SLC39A5) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  17. US 12082566

    Rodent animals expressing human CR1

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  18. US 12082565

    Non-human animals models of retinoschisis

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  19. US 12077570

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  20. US 12077587

    Anti-CD8 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  21. US 12077782

    Viral clearance by low pH hold

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  22. US 12077593

    Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  23. US 12070502

    Process for reducing subvisible particles in a pharmaceutical formulation

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 27, 2024 · Expires Aug 22, 2044

    granted
  24. US 12070460

    Methods of treating skin cancer with Carboxypeptidase Vitellogenic Like (CPVL) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 27, 2024 · Expires Aug 22, 2044

    granted